Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PKM2 Inhibitor
MTP is a potent inhibitor of pyruvate kinase M2 (PKM2) that induces apoptosis in cancer cells through the modulation of caspase-3 activation. Additionally, MTP promotes autophagy and enhances reactive oxygen species (ROS) generation, while also inhibiting JAK2 signaling pathways. This compound is particularly valuable for research applications focused on oral squamous cell carcinoma and related cancer studies. -
TrxR Inhibitor
PAO-Nap is a selective thioredoxin reductase (TrxR) inhibitor modified with a naphthalimide fluorophore linked via aminocaproic acid. This compound induces oxidative stress-mediated apoptosis in HL-60 cells, making it a valuable tool for studying apoptotic pathways and oxidative stress mechanisms in cancer research. Its unique fluorescent properties also facilitate real-time monitoring of cellular responses to TrxR inhibition. -
PDE6/NAMPT Inhibitor
PDEδ/NAMPT IN-1 is a potent dual inhibitor targeting phosphodiesterase 6 (PDE6) with a binding affinity of 0.410 nM and nicotinamide phosphoribosyl transferase (NAMPT) with an IC50 of 2.21 nM. This compound effectively disrupts KRAS-related signaling pathways and hampers the synthesis of nicotinamide adenine dinucleotide (NAD+), leading to apoptosis in KRAS mutant pancreatic cancer cells. PDEδ/NAMPT IN-1 holds significant potential for advancing research in KRAS mutant pancreatic cancer. -
Monoamine Oxidase Inhibitor
Harmol hydrochloride is a potent monoamine oxidase inhibitor that functions as a transcription factor EB (TFEB) activator. It demonstrates significant biological activities, including the induction of cell mitosis, autophagy, and apoptosis. Additionally, Harmol hydrochloride promotes the degradation of α-synuclein by modulating the autophagy-lysosomal pathway, making it relevant in studies of neurodegenerative diseases. Its diverse pharmacological effects also extend to anti-tumor, anti-depressant, and anti-aging activities, and it has shown promise in alleviating motor impairments in models of Parkinson's disease. -
Cathepsin B/CANP Inhibitor
NCO-700 is a potent dual inhibitor of cathepsin B and calcium-activated neutral protease (CANP), exhibiting IC50 values of 0.8 μM and 46 μM, respectively. This compound effectively reduces myocardial fibrin degradation by inhibiting protease activity and demonstrates significant anti-tumor effects on hormone-independent cancer cells, including prostate cancer, by inducing apoptosis. NCO-700 serves as a valuable tool for investigating mechanisms underlying myocardial ischemia and exploring novel treatments for refractory hormone-independent tumors. -
IDO1/TrxR Inhibitor
ZC0101 is a potent dual inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase (TrxR), exhibiting IC50 values of 0.084 μM and 7.98 μM, respectively. This compound demonstrates significant biological activity by inducing apoptosis and promoting reactive oxygen species (ROS) accumulation in cancer cells. ZC0101 is a valuable tool for research applications aimed at understanding cancer cell metabolism and exploring therapeutic strategies targeting IDO1 and TrxR pathways. -
Hsp-Cdc Inhibitor
Hsp90-Cdc37-IN-2 is a selective inhibitor of the interaction between heat shock protein 90 (Hsp90) and cyclin 37 (Cdc37). This compound exhibits potent anti-proliferative activity against cancer cell lines A549, MCF-7, HOS, and HepG2, with IC50 values ranging from 0.41 to 0.94 μM. Hsp90-Cdc37-IN-2 effectively disrupts mitochondrial membrane potential, induces apoptosis, and causes cell cycle arrest at the G0/G1 phase in A549 cells, making it a valuable tool for cancer research and therapeutic investigations. -
ChA Inhibitor
α-NETA is a potent noncompetitive inhibitor of choline acetyltransferase (ChA), exhibiting an IC50 value of 9 μM. Additionally, it displays strong antagonistic activity against aldehyde dehydrogenase 1A1 (ALDH1A1) with an IC50 of 0.04 µM and also targets chemokine-like receptor-1 (CMKLR1). While it shows some inhibitory effects on cholinesterase (ChE) and acetylcholinesterase (AChE) with higher IC50 values, α-NETA is notable for its anti-cancer properties, making it a valuable tool for research in cancer biology and neuropharmacology. -
CYP450 ω-Hydroxylase Inhibitor
17-ODYA is a selective CYP450 ω-hydroxylase inhibitor, demonstrating potent inhibition (IC50<100 nM) of 20-hydroxyeicosatetraenoic acid (20-HETE) and related eicosanoids in rat renal cortical microsomes. This compound effectively prevents isoproterenol-induced apoptosis and necrosis in cultured cardiomyocytes. Additionally, 17-ODYA serves as a click chemistry reagent with an alkyne group, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, making it a valuable tool for various biochemical applications. -
SCD1 Inhibitor
SSI-4 is a potent stearoyl-CoA desaturase (SCD1) inhibitor with an EC50 of 1.9 nM for mouse SCD1. By blocking the conversion of saturated fatty acids to monounsaturated fatty acids, SSI-4 effectively reduces oleic and palmitoleic acid production. It promotes lipid peroxidation, induces endoplasmic reticulum stress, and activates apoptotic pathways. Additionally, SSI-4 inhibits mTORC1 activity, suppresses B cell proliferation and antibody production, and induces autophagy. This compound is valuable for studies related to cancers such as acute myeloid leukemia and renal cell carcinoma, as well as influenza infections. -
Monoamine Oxidase Inhibitor
4-Hydroxyderricin is a selective inhibitor of Monoamine Oxidase B (MAO-B) with an IC50 of 3.43 μM, making it a valuable tool for studying neurological conditions. In addition to its primary mechanism, it exhibits mild inhibition of dopamine β-hydroxylase activity. This compound has demonstrated a range of biological activities, including antidepressant, anti-allergic, anti-diabetic, antioxidant, and antitumor effects. It has been shown to induce apoptosis and cell cycle arrest in hepatocellular carcinoma cells via modulation of the PI3K/AKT/mTOR pathway, as well as enhance osteoblast differentiation while inhibiting osteoclast formation, positioning it as a promising candidate for research into inflammatory diseases. -
α-mannosidases inhibitor
Kifunensine is a potent and selective inhibitor of class I α-mannosidases, originally isolated from *Actinomycete* species. It blocks the trimming of mannose residues from N-linked glycoproteins by inhibiting α-mannosidase I activity, thereby preventing proper glycoprotein maturation. Through this mechanism, Kifunensine disrupts endoplasmic reticulum–associated degradation (ERAD) pathways, leading to the accumulation of misfolded glycoproteins. It is widely used as a biochemical tool in studies of protein folding, quality control, and glycosylation. -
TrxR-1 inhibitor
Manumycin A is a polyketide antibiotic that functions as an inhibitor of thioredoxin reductase 1 (TrxR-1). It exhibits anti-tumor activity by inhibiting breast cancer cell growth, potentially through LC3-mediated mechanisms. Manumycin A also downregulates pro-inflammatory cytokine release in TNF-α-stimulated human monocytes, indicating anti-inflammatory potential. Additionally, it inhibits the Ras/Raf/ERK1/2 signaling pathway and hnRNP H1 in castration-resistant prostate cancer cells, thereby suppressing exosome biogenesis and secretion. -
PCSK9 inhibitor
PF-06446846 hydrochloride is an orally active and highly selective inhibitor of the translation of proprotein convertase subtilisin/kexin type 9 (PCSK9). It inhibits PCSK9 expression by inducing ribosomal stalling at approximately codon 34 during translation. -
BRD4/NAMPT inhibitor
BRD4/NAMPT-IN-1 (Compound A2) is a dual inhibitor of NAMPT and BRD4, with IC₅₀ values of 35 nM and 58 nM, respectively. It suppresses the growth and migration of hepatocellular carcinoma cells and induces apoptosis. In the HCCLM3 xenograft mouse model, BRD4/NAMPT-IN-1 exhibits potent anticancer activity without apparent toxicity. -
NNMT inhibitor
NNMTi is a potent nicotinamide N-methyltransferase (NNMT) inhibitor with an IC₅₀ of 1.2 μM. It selectively binds to residues within the NNMT substrate-binding site. NNMTi promotes myoblast differentiation in vitro and enhances the fusion and regenerative capacity of muscle stem cells (muSCs) in aged mice, making it a promising compound for research into muscle regeneration and age-related muscle decline. -
MMP Inhibitor/PPARα Agonists
Auraptene is an orally active geranyloxycoumarin compound naturally found in plants of the *Brassicaceae* family. It exhibits a wide range of biological activities, including antibacterial, anti-pathogenic, antioxidant, anti-tumor, and neuroprotective effects. Auraptene has shown therapeutic potential in the management of various chronic conditions such as hypertension and cystic fibrosis, making it a valuable compound for pharmacological and nutraceutical research. -
COX/LOX inhibitor
Phenidone is an orally active dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX) pathways, exhibiting anti-inflammatory and immunomodulatory effects. It has been shown to ameliorate paralysis in rat models of experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. Phenidone also acts as a potent hypotensive agent in spontaneously hypertensive rats. Additionally, it has a long-standing application as a photographic developer due to its redox properties. -
HO-1 inhibitor
Tin protoporphyrin IX dichloride (SnPPIX) is a potent inhibitor of heme oxygenase-1 (HO-1), an enzyme involved in cellular stress responses and tumor progression. SnPPIX has been shown to sensitize pancreatic ductal adenocarcinoma (PDAC) tumors to chemotherapy in mouse models, enhancing therapeutic efficacy and supporting its potential use as a chemosensitizing agent in cancer treatment. -
20-HETE synthase inhibitor
HET0016 is a potent and selective inhibitor of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase, with IC50 values of 17.7 nM, 12.1 nM, and 20.6 nM for CYP4A1-, CYP4A2-, and CYP4A3-mediated 20-HETE synthesis, respectively. It also acts as a selective cytochrome P450 (CYP450) inhibitor and has been shown to suppress angiogenesis and tumor growth, making it a valuable compound for cancer and vascular research. -
LOX inhibitor
LXG6403 is a highly potent and irreversible lysyl oxidase (LOX) inhibitor that efficiently suppresses cellular LOX activity in MDA-MB-231 cells with an IC50 of 1.3 μM. It exhibits over 3-fold selectivity for LOX over LOXL2 and shows no inhibitory activity against LOXL1, making it a valuable tool for studying LOX-specific functions in cancer and fibrosis research. -
Cathepsin L inhibitor
Z-FY-CHO (Z-Phe-Tyr-CHO) is a potent and specific inhibitor of cathepsin L (CTSL), a lysosomal cysteine protease involved in protein degradation and various pathological processes. It is commonly used as a tool compound in studies of CTSL-related functions and diseases. -
DNA gyrase inhibitor/Hsp90 antagonist
Novobiocin (Albamycin) is a potent and orally active antibiotic that functions as a DNA gyrase inhibitor and a heat shock protein 90 (Hsp90) antagonist. It holds potential for research into highly β-lactam-resistant pneumococcal infections and has demonstrated antiviral activity against orthopoxviruses. -
PCSK9 inhibitor
AZD0780 (PCSK9-IN-12) is a heteroaryl compound with high binding affinity for proprotein convertase subtilisin/kexin type 9 (PCSK9), exhibiting a Kd value of <200 nM. It is a valuable tool for research in cholesterol metabolism and PCSK9-related therapeutic pathways. -
Endoplasmic Reticulum Stress Inhibitor
Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an inhibitor of endoplasmic reticulum (ER) stress that significantly downregulates pro-apoptotic molecules, including caspase-3 and caspase-12. Additionally, it suppresses ERK signaling, contributing to its cytoprotective and anti-apoptotic effects. -
ADAM17 inhibitor
JG26 is a potent ADAM inhibitor with IC50 values of 12 nM for ADAM8, 1.9 nM for ADAM17, and 150 nM for ADAM10. It also inhibits MMP-12 with an IC50 of 9.4 nM. JG26 suppresses AngII-induced EGFR transactivation and ERK activation, upregulates ACE2 expression, inhibits CD23 shedding, and reduces SARS-CoV-2 infection. Additionally, JG26 demonstrates anti-metastatic effects in colorectal cancer and holds research potential in Hodgkin lymphoma and vascular diseases. -
EGFR/PI3K Inhibitor
MTX-531 is an orally active small molecule that inhibits EGFR (IC50 = 14.7 nM) and multiple PI3K isoforms, with IC50 values of 6.4 nM (PI3Kα), 233 nM (PI3Kβ), 8.3 nM (PI3Kγ), and 1.1 nM (PI3Kδ), demonstrating potent antitumor activity. Additionally, MTX-531 functions as a weak PPARγ agonist (IC50 = 2.5 µM), which may mitigate PI3K inhibitor-induced hyperglycemia. -
Hsp90/HSV inhibitor
AT-533 is a potent inhibitor of heat shock protein 90 (Hsp90) and herpes simplex virus (HSV), exhibiting strong antitumor and antiviral activities. It suppresses tumor growth and angiogenesis by disrupting the HIF-1α/VEGF/VEGFR-2 signaling axis, a critical pathway in tumor vascularization and progression. Additionally, AT-533 inhibits key downstream signaling cascades, including Akt/mTOR/p70S6K, ERK1/2, and FAK pathways. In endothelial cells, specifically human umbilical vein endothelial cells (HUVECs), AT-533 effectively inhibits tube formation, cell migration, and invasion, highlighting its anti-angiogenic properties. These combined effects position AT-533 as a promising candidate for cancer therapy and angiogenesis-related disease research. -
POLRMT inhibitor
IMT1 is a first-in-class, specific, and noncompetitive inhibitor of human mitochondrial RNA polymerase (POLRMT). It induces a conformational change in POLRMT, preventing substrate binding and inhibiting transcription in a dose-dependent manner in vitro. IMT1 decreases deoxynucleoside triphosphate levels and citric acid cycle intermediates, leading to significant depletion of cellular amino acid levels. IMT1 holds potential for the treatment of diseases associated with mitochondrial transcription disorders. -
PDE4/NF-κB inhibitor
Sappanone A is an orally active homoisoflavone isolated from Caesalpinia sappan L., exhibiting notable anti-inflammatory and antioxidant properties. It functions as an inhibitor of phosphodiesterase 4 (PDE4) and NF-κB, key regulators of inflammatory signaling. Additionally, Sappanone A activates the Nrf2 pathway, leading to increased expression of the cytoprotective enzyme heme oxygenase-1 (HO-1). Sappanone A also inhibits RANKL-induced osteoclastogenesis, suggesting potential benefits in bone metabolism disorders. With its multifaceted bioactivity, Sappanone A holds significant promise for research in inflammation-related diseases, cardiovascular conditions, and bone health. -
phospholipase A2/HDAC2 inhibitor
Rhamnetin is a naturally occurring flavonoid and quercetin derivative found in *Coriandrum sativum*. It functions as an inhibitor of secretory phospholipase A₂ and histone deacetylase 2 (HDAC2), contributing to its broad pharmacological profile. Rhamnetin exhibits notable antitumor, antioxidant, and anti-inflammatory activities, making it a promising compound for research in cancer, oxidative stress-related conditions, and inflammatory diseases. -
COX-1/HDAC/Tyrosinase Inhibitor
Gnetol is a bioactive phenolic compound isolated from the root of *Gnetum montanum* with diverse pharmacological properties. It potently inhibits cyclooxygenase-1 (COX-1) with an IC₅₀ of 0.78 μM and exhibits histone deacetylase (HDAC) inhibitory activity. Gnetol is also a strong tyrosinase inhibitor, with an IC₅₀ of 4.5 μM against murine tyrosinase, leading to suppression of melanin biosynthesis. In addition to its antioxidant, antiproliferative, anticancer, and hepatoprotective effects, Gnetol modulates metabolic enzymes in a concentration-dependent manner, including α-amylase, α-glucosidase, and adipogenesis pathways, making it a promising candidate for research in oncology, dermatology, and metabolic disorders. -
Ferroptosis inhibitor
SRS11-92 is a potent ferroptosis inhibitor and structural analogue of Ferrostatin-1 (Fer-1). It effectively blocks Erastin-induced ferroptotic cell death in HT-1080 human fibrosarcoma cells, with an EC₅₀ of 6 nM. SRS11-92 serves as a valuable tool for studying ferroptosis and its therapeutic modulation in oxidative stress-related diseases and cancer. -
MAO/LSD1 Inhibitor
Tranylcypromine hemisulfate is an irreversible, nonselective inhibitor of monoamine oxidase (MAO) and also acts as a lysine-specific demethylase 1 (LSD1) inhibitor. This compound demonstrates notable antidepressant effects and is utilized in the treatment of depression. Additionally, tranylcypromine hemisulfate has been shown to suppress lesion growth and alleviate generalized hyperalgesia in mouse models of induced endometriosis, making it a valuable tool for research in both psychiatric and pain-related studies. -
PDE Inhibitor
Theophylline sodium acetate functions as a potent phosphodiesterase (PDE) inhibitor, specifically targeting PDE3 to promote the relaxation of airway smooth muscle. It also acts as an adenosine receptor antagonist and histone deacetylase (HDAC) activator, contributing to its anti-inflammatory properties by elevating IL-10 levels and inhibiting NF-κB translocation to the nucleus. Additionally, Theophylline sodium acetate is known to induce apoptosis, making it a valuable reagent for research on asthma and chronic obstructive pulmonary disease (COPD). -
PDE4 Inhibitor
PDE4-IN-10 is a selective phosphodiesterase 4 (PDE4) inhibitor, exhibiting an IC50 of 7.01 μM for the PDE4B isoform. This compound demonstrates significant biological activity by inhibiting TNF-α production and exhibits microsomal stability, making it suitable for various in vitro applications. PDE4-IN-10 is a valuable tool for research aimed at understanding inflammatory processes and developing therapeutic strategies for related diseases. -
HSP90 Inhibitor
SST0116CL1 free base is a potent inhibitor of the heat shock protein 90 (HSP90) with an IC50 of 0.21 μM. It selectively binds to the ATP binding pocket of HSP90, disrupting its chaperone activity and leading to the degradation of client proteins such as EGFR, CDK4, and AKT. SST0116CL1 free base has demonstrated significant antiproliferative effects, including the degradation of Her2 in BT-474 cells (IC50: 0.2 μM), and is applicable in the study of leukemia, gastric cancer, and ovarian carcinoma. -
HSP90 Inhibitor
SST0116CL1 is a potent HSP90 inhibitor with an IC50 of 0.21 μM. This compound binds to the ATP binding pocket of HSP90, disrupting its chaperone function and promoting the degradation of client proteins such as EGFR, CDK4, and AKT. SST0116CL1 demonstrates antiproliferative activity and is effective in reducing Her2 levels in BT-474 cells (IC50: 0.2 μM). It is suitable for research applications involving leukemia, gastric carcinoma, and ovarian carcinoma. -
PKM2/PDK1 Inhibitor
PKM2/PDK1-IN-1 is a dual inhibitor targeting pyruvate kinase M2 (PKM2) and pyruvate dehydrogenase kinase 1 (PDK1). It demonstrates significant biological activity by inhibiting the proliferation of non-small cell lung cancer (NSCLC) cells and inducing apoptosis. This compound promotes intercellular reactive oxygen species (ROS) production and modulates apoptotic proteins, engaging both mitochondrial and death receptor pathways in cancer cell death. Its unique mechanism makes it a valuable tool for research in cancer biology and therapeutic development. -
HSP90 Inhibitor
DDO-6600 is a covalent inhibitor of Hsp90, targeting its interaction with the co-chaperone protein Cdc37. This mechanism leads to the degradation of client kinases, including AKT, CDK4, and c-Raf, and exhibits potent inhibitory activity against various cancer cell lines. Notably, DDO-6600 reduces migration and invasion of HCT-116 cells while inducing cell cycle arrest and apoptosis. In vivo studies demonstrate its significant efficacy in inhibiting tumor growth in the HCT-116 xenograft model, making it a valuable tool for research in colorectal cancer. -
HSP90 Inhibitor
HVH-2930 is a potent inhibitor of heat shock protein 90 (HSP90), demonstrated to significantly impair the viability of BT474 and JIMT-1 breast cancer cell lines, with IC50 values of 6.86 μM and 4.42 μM, respectively. This compound mediates its effects by downregulating critical HSP90 client proteins, including HER2, p-HER2, AKT, p-AKT, cyclin D1, and survivin. In preclinical studies, HVH-2930 has shown notable antitumor efficacy in mouse models and possesses favorable pharmacokinetic properties in vivo, positioning it as a valuable tool for cancer research focused on HSP90 inhibition. -
HSP90AB1/EEF1A1 Inhibitor
Gamendazole is a selective inhibitor targeting HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A). It effectively binds to the C-terminal nucleotide binding pocket of HSP90, leading to the downregulation of key clients such as AKT1 and ERBB2 while stabilizing the HSP90 heterocomplex. Additionally, Gamendazole specifically inhibits the actin bundling activity of EEF1A1 without affecting its ribosomal functions, making it a valuable tool for studying protein interactions and mechanisms. Furthermore, Gamendazole exhibits antispermatogenic properties, suggesting potential applications in developing reversible non-hormonal male contraceptives. -
Angiotensin Receptor Inhibitor
YS-49 monohydrate is a selective angiotensin receptor inhibitor, primarily targeting the angiotensin II pathway. This compound effectively reduces angiotensin II-stimulated proliferation of vascular smooth muscle cells by inducing heme oxygenase-1, offering potential therapeutic insights for cardiovascular research. Additionally, as an isoquinoline alkaloid, YS-49 demonstrates significant positive inotropic effects through the activation of cardiac β-adrenoceptors, making it a valuable reagent for studies involving cardiac function and vascular biology. -
hMAO-A Inhibitor
Osthenol is a reversible and selective competitive inhibitor of human monoamine oxidase A (hMAO-A), with an IC50 of 0.74 μM and a Ki of 0.26 μM. This compound exhibits both antifungal and antibacterial properties, while also modulating the oxidative deamination of monoamine neurotransmitters. Additionally, Osthenol has been shown to inhibit the PI3K/AKT signaling pathway, leading to apoptosis in colon cancer cells, G1 phase cell cycle arrest, and reduced cell proliferation. Its applications are significant in the study of neurological disorders and cancer, particularly in targeting MAO-A for depression and investigating mechanisms in colon cancer. -
PDE Inhibitor
Theophylline L-lysine is a soluble derivative of Theophylline that primarily acts as a phosphodiesterase (PDE) inhibitor. It effectively inhibits PDE3 activity, which leads to relaxation of airway smooth muscle and exhibits anti-inflammatory properties through the enhancement of IL-10 levels and the inhibition of NF-κB nuclear translocation. Additionally, Theophylline L-lysine induces apoptosis, making it a valuable compound for research applications in asthma and chronic obstructive pulmonary disease (COPD). -
PDE4 Inhibitor
AN-2898 is a selective phosphodiesterase 4 (PDE4) inhibitor with an IC50 of 0.027 μM, demonstrating significant potency over other phosphodiesterase enzymes, including PDE1A, PDE2A, and PDE3A. It effectively inhibits PDE4 subtypes such as PDE4B1, PDE4A1A, and PDE4D2. AN-2898 significantly reduces the production of pro-inflammatory cytokines including TNF-α, IL-2, IFN-γ, IL-5, and IL-10, making it a valuable reagent for research applications in mild to moderate atopic dermatitis and psoriasis. -
PDE4 Inhibitor
LY2775240 is a potent and selective phosphodiesterase 4 (PDE4) inhibitor, demonstrating significant inhibitory activity against PDE4A, PDE4B, and PDE4D with IC₅₀ values of 0.09 nM and 0.14 nM for the latter two, as well as an IC₅₀ of 2.4 nM for PDE4C. This compound effectively reduces TNFα production during immune activation, making it valuable for studies investigating inflammatory conditions. LY2775240 is particularly relevant for research focused on psoriasis, as evidenced by its efficacy in lowering TNFα levels in rodent and cynomolgus monkey models. -
FASN/SCD Inhibitor
FASN/SCD-IN-1 is a potent inhibitor of Fatty Acid Synthase (FASN) and Stearoyl-CoA Desaturase (SCD), derived from Silybin. This orally active compound exhibits significant biological activities, including the inhibition of lipid deposition and reduction of FASN and SCD transcription levels. Additionally, FASN/SCD-IN-1 demonstrates antioxidant, anti-inflammatory, and anti-fibrotic properties, with notable hepatoprotective effects in rat models of acute liver injury. Its ability to ameliorate pathological features such as steatosis, inflammation, and fibrosis in mouse models of myeloproliferative steatohepatitis (MASH) makes it a valuable tool for exploring mechanisms underlying MASH-related liver conditions. -
PDE4 Inhibitor
ASP9831 is an orally active phosphodiesterase type 4 (PDE4) inhibitor. It effectively inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNF-α) production, demonstrating notable anti-inflammatory properties. This compound is valuable for research applications centered on fatty liver disease and related inflammatory conditions. -
PDE4 Inhibitor
Revamilast is an orally active phosphodiesterase-4 (PDE4) inhibitor with a reported IC50 of 3 nM. This compound effectively inhibits the production of tumor necrosis factor-alpha (TNF-α), making it a valuable tool for research into inflammatory conditions. Applications include studies related to rheumatoid arthritis, plaque psoriasis, asthma, and other related inflammatory diseases.
